Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Cancer cells evade immune detection through immunosuppression.
• Tumor-induced immunosuppression hinders immune responses and cancer immunotherapy effectiveness.
• Identifying novel immunosuppressive pathways is crucial for developing better cancer treatments.

Purpose of the Study:

• To elucidate a novel immunosuppressive pathway involving adenosine, Casitas B-lineage lymphoma b (Cbl-b), and Notch1.
• To investigate the role of the Cbl-b-Notch1 axis in regulating CD8+ T-cell effector functions.
• To evaluate the therapeutic potential of targeting this axis in cancer immunotherapy.

Main Methods:

• Utilized genetic knockout and pharmacological inhibition of Cbl-b in cancer models.
• Assessed the impact of adenosine on Notch1 degradation and T-cell function.
• Measured CD8+ T-cell effector functions, anti-cancer responses, and resistance to immunosuppression.

Main Results:

• Adenosine promotes Cbl-b-mediated Notch1 degradation, suppressing CD8+ T-cell effector functions.
• Genetic or pharmacological inhibition of Cbl-b blocked Notch1 degradation and reactivated Notch1 signaling.
• Reactivation of Notch1 signaling enhanced CD8+ T-cell effector functions, leading to improved anti-cancer responses and immunosuppression resistance.

Conclusions:

• The Cbl-b-Notch1 axis represents a newly identified immunosuppressive pathway in cancer.
• Targeting Cbl-b to prevent Notch1 degradation is a promising strategy for enhancing cancer immunotherapy.
• This approach offers a potential method to overcome tumor-induced immunosuppression and improve treatment efficacy.